470 related articles for article (PubMed ID: 32806517)
21. [Not Available].
Mosca M; Vertenoeil G; Toppaldoddi KR; Plo I; Vainchenker W
Bull Cancer; 2016 Jun; 103(6 Suppl 1):S16-28. PubMed ID: 27494969
[TBL] [Abstract][Full Text] [Related]
22. The Hematopoietic Microenvironment in Myeloproliferative Neoplasms: The Interplay Between Nature (Stem Cells) and Nurture (the Niche).
Zhan H; Kaushansky K
Adv Exp Med Biol; 2020; 1273():135-145. PubMed ID: 33119879
[TBL] [Abstract][Full Text] [Related]
23. The differential diagnosis of classical myeloproliferative neoplasms (MPN): the updated WHO criteria.
Kvasnicka HM
Rinsho Ketsueki; 2019; 60(9):1166-1175. PubMed ID: 31597840
[TBL] [Abstract][Full Text] [Related]
24. Characterization and Prognosis Significance of JAK2 (V617F), MPL, and CALR Mutations in Philadelphia-Negative Myeloproliferative Neoplasms.
Singdong R; Siriboonpiputtana T; Chareonsirisuthigul T; Kongruang A; Limsuwanachot N; Sirirat T; Chuncharunee S; Rerkamnuaychoke B
Asian Pac J Cancer Prev; 2016 Oct; 17(10):4647-4653. PubMed ID: 27892678
[TBL] [Abstract][Full Text] [Related]
25. Mutations, inflammation and phenotype of myeloproliferative neoplasms.
Hermouet S
Front Oncol; 2023; 13():1196817. PubMed ID: 37284191
[TBL] [Abstract][Full Text] [Related]
26. Calreticulin haploinsufficiency augments stem cell activity and is required for onset of myeloproliferative neoplasms in mice.
Shide K; Kameda T; Kamiunten A; Ozono Y; Tahira Y; Yokomizo-Nakano T; Kubota S; Ono M; Ikeda K; Sekine M; Akizuki K; Nakamura K; Hidaka T; Kubuki Y; Iwakiri H; Hasuike S; Nagata K; Sashida G; Shimoda K
Blood; 2020 Jul; 136(1):106-118. PubMed ID: 32219445
[TBL] [Abstract][Full Text] [Related]
27. Coexisting JAK2V617F and CALR Exon 9 Mutations in Myeloproliferative Neoplasms - Do They Designate a New Subtype?
Ahmed RZ; Rashid M; Ahmed N; Nadeem M; Shamsi TS
Asian Pac J Cancer Prev; 2016; 17(3):923-6. PubMed ID: 27039813
[TBL] [Abstract][Full Text] [Related]
28. Biology and therapeutic targeting of molecular mechanisms in MPNs.
How J; Garcia JS; Mullally A
Blood; 2023 Apr; 141(16):1922-1933. PubMed ID: 36534936
[TBL] [Abstract][Full Text] [Related]
29. JAK2 and MPL mutations in myeloproliferative neoplasms: discovery and science.
Kilpivaara O; Levine RL
Leukemia; 2008 Oct; 22(10):1813-7. PubMed ID: 18754026
[TBL] [Abstract][Full Text] [Related]
30. Allogeneic Hematopoietic Cell Transplantation for Leukemic Transformation Preceded by Philadelphia Chromosome-Negative Myeloproliferative Neoplasms: A Nationwide Survey by the Adult Acute Myeloid Leukemia Working Group of the Japan Society for Hematopoietic Cell Transplantation.
Takagi S; Masuoka K; Uchida N; Kurokawa M; Nakamae H; Imada K; Iwato K; Ichinohe T; Atsuta Y; Takami A; Yano S
Biol Blood Marrow Transplant; 2016 Dec; 22(12):2208-2213. PubMed ID: 27667010
[TBL] [Abstract][Full Text] [Related]
31. Somatic Mutations in Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Ferreira Cristina S; Polo B; Lacerda JF
Semin Hematol; 2018 Oct; 55(4):215-222. PubMed ID: 30502850
[TBL] [Abstract][Full Text] [Related]
32. The Rationale for Immunotherapy in Myeloproliferative Neoplasms.
Masarova L; Bose P; Verstovsek S
Curr Hematol Malig Rep; 2019 Aug; 14(4):310-327. PubMed ID: 31228096
[TBL] [Abstract][Full Text] [Related]
33. Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both.
Koschmieder S; Mughal TI; Hasselbalch HC; Barosi G; Valent P; Kiladjian JJ; Jeryczynski G; Gisslinger H; Jutzi JS; Pahl HL; Hehlmann R; Maria Vannucchi A; Cervantes F; Silver RT; Barbui T
Leukemia; 2016 May; 30(5):1018-24. PubMed ID: 26854026
[TBL] [Abstract][Full Text] [Related]
34. Recent advances in therapies for primary myelofibrosis.
Vainchenker W; Yahmi N; Havelange V; Marty C; Plo I; Constantinescu SN
Fac Rev; 2023; 12():23. PubMed ID: 37771602
[TBL] [Abstract][Full Text] [Related]
35. [Clinical Analysis of Driver Mutations in Patients with Ph Negative Myeloproliferative Neoplasms].
He ZP; Tian HY; Tan M; Wu Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):842-848. PubMed ID: 29950230
[TBL] [Abstract][Full Text] [Related]
36. Immunotherapy for myeloproliferative neoplasms (MPN).
Hofmann S; Babiak A; Greiner J
Curr Cancer Drug Targets; 2011 Jan; 11(1):72-84. PubMed ID: 21062247
[TBL] [Abstract][Full Text] [Related]
37. Somatic mutations of calreticulin in myeloproliferative neoplasms.
Klampfl T; Gisslinger H; Harutyunyan AS; Nivarthi H; Rumi E; Milosevic JD; Them NC; Berg T; Gisslinger B; Pietra D; Chen D; Vladimer GI; Bagienski K; Milanesi C; Casetti IC; Sant'Antonio E; Ferretti V; Elena C; Schischlik F; Cleary C; Six M; Schalling M; Schönegger A; Bock C; Malcovati L; Pascutto C; Superti-Furga G; Cazzola M; Kralovics R
N Engl J Med; 2013 Dec; 369(25):2379-90. PubMed ID: 24325356
[TBL] [Abstract][Full Text] [Related]
38. Role of hematopoietic stem cell transplantation in patients with myeloproliferative disease.
Salit RB; Deeg HJ
Hematol Oncol Clin North Am; 2014 Dec; 28(6):1023-35. PubMed ID: 25459177
[TBL] [Abstract][Full Text] [Related]
39. Philadelphia chromosome-negative myeloproliferative disorders: biology and treatment.
Hoffman R; Prchal JT; Samuelson S; Ciurea SO; Rondelli D
Biol Blood Marrow Transplant; 2007 Jan; 13(1 Suppl 1):64-72. PubMed ID: 17222772
[TBL] [Abstract][Full Text] [Related]
40. Bone Marrow Soluble Mediator Signatures of Patients With Philadelphia Chromosome-Negative Myeloproliferative Neoplasms.
Cominal JG; Cacemiro MDC; Berzoti-Coelho MG; Pereira IEG; Frantz FG; Souto EX; Covas DT; de Figueiredo-Pontes LL; Oliveira MC; Malmegrim KCR; de Castro FA
Front Oncol; 2021; 11():665037. PubMed ID: 34084749
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
